The effect of injection of Mitomycin c and Bevacizumab on intraocular pressure after Ahmed Glaucoma Valve (AGV) implantation surgery

The effect of injection combination of Mitomycin c and Bevacizumab on outcome of intraocular pressure after Ahmed Glaucoma Valve (AGV) implantation surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211207053323N1

Enrollment

Registered

2022-10-19

Start date

2021-12-16

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular glaucoma. Unspecified open-angle glaucoma, stage unspecified

Interventions

Intervention 1: Intervention group: to insert the AGV (scleral patch graft, scleral tunnel), the conjunctiva is cut 4 mm away from the limbus in the upper outer quadrant. 20 mg of triamcinolone is inj

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient with uncontroll glaucoma and indicated for shunt

Exclusion criteria

Exclusion criteria: Age below 18 years Neovascular glaucoma secondary to tumor or uveitis Follow up less than 6 months Previous shunt devices Simultaneous intravitreal injection of bevacizumab (IVB) Non-diabetic people with a history of failed trabeculectomy surgery

Design outcomes

Primary

Measure	Time frame
Intraocular pressure reduction percentage after surgery. Timepoint: One week, four weeks, six weeks, eight weeks, three months and 6 months are followed. Method of measurement: Applanation tonometer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEmad Soleimani Bayatiani

Ahvaz University of Medical Sciences

emadf14@yahoo.com+98 21 2245 4292

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026